Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.

This is a report on off-label extended use of rFVIIa in managing pulmonary, vesical and GI haemorrhage in 3 patients post-BMT, who failed to respond to blood component transfusion and haemostatic medications. rFVIIa resulted in partial control of haemorrhage in 2 patients, and no effect in the third. No toxicity or adverse events were noted.

– M. Aldouri.